COLLEGIUM PHARMACEUTICAL ($COLL) posted quarterly earnings results for Q4 2025 on Thursday, February 26th. The company reported earnings of $2.04 per share, missing estimates of $2.37 by $0.33. The company also reported revenue of $205,450,000, missing estimates of $210,489,240 by $-5,039,240.
You can see Quiver Quantitative's $COLL stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
COLLEGIUM PHARMACEUTICAL Insider Trading Activity
COLLEGIUM PHARMACEUTICAL insiders have traded $COLL stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $COLL stock by insiders over the last 6 months:
- JOHN A. FALLON sold 34,853 shares for an estimated $1,645,535
- COLLEEN TUPPER (EVP & Chief Financial Officer) has made 0 purchases and 2 sales selling 30,000 shares for an estimated $1,215,753.
- SCOTT DREYER (EVP & Chief Commercial Officer) has made 0 purchases and 2 sales selling 17,600 shares for an estimated $847,855.
- THOMAS B SMITH (EVP and Chief Medical Officer) sold 17,478 shares for an estimated $671,576
- RITA J. BALICE-GORDON sold 3,650 shares for an estimated $171,673
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
COLLEGIUM PHARMACEUTICAL Hedge Fund Activity
We have seen 133 institutional investors add shares of COLLEGIUM PHARMACEUTICAL stock to their portfolio, and 138 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RUBRIC CAPITAL MANAGEMENT LP removed 1,330,062 shares (-47.1%) from their portfolio in Q4 2025, for an estimated $61,581,870
- JANUS HENDERSON GROUP PLC added 538,337 shares (+59.1%) to their portfolio in Q4 2025, for an estimated $24,925,003
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ added 518,721 shares (+65.3%) to their portfolio in Q4 2025, for an estimated $24,016,782
- EVENTIDE ASSET MANAGEMENT, LLC removed 514,673 shares (-21.5%) from their portfolio in Q4 2025, for an estimated $23,829,359
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 510,060 shares (+1512.9%) to their portfolio in Q4 2025, for an estimated $23,615,778
- ASSENAGON ASSET MANAGEMENT S.A. added 316,109 shares (+161.6%) to their portfolio in Q4 2025, for an estimated $14,635,846
- D. E. SHAW & CO., INC. added 264,099 shares (+67.8%) to their portfolio in Q4 2025, for an estimated $12,227,783
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
COLLEGIUM PHARMACEUTICAL Analyst Ratings
Wall Street analysts have issued reports on $COLL in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 01/09/2026
- Needham issued a "Buy" rating on 01/08/2026
- Truist Securities issued a "Buy" rating on 11/07/2025
To track analyst ratings and price targets for COLLEGIUM PHARMACEUTICAL, check out Quiver Quantitative's $COLL forecast page.
COLLEGIUM PHARMACEUTICAL Price Targets
Multiple analysts have issued price targets for $COLL recently. We have seen 4 analysts offer price targets for $COLL in the last 6 months, with a median target of $56.0.
Here are some recent targets:
- Glen Santangelo from Barclays set a target price of $56.0 on 01/09/2026
- Brandon Folkes from HC Wainwright & Co. set a target price of $60.0 on 01/09/2026
- Serge Belanger from Needham set a target price of $56.0 on 01/08/2026
- Les Sulewski from Truist Securities set a target price of $48.0 on 11/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
